News Interim report for 1H 2023 Please read the full announcement in PDF Attachment 2023_54_Q22023_CompanyAnnouncement Continue Reading Previous Novartis remibrutinib Phase III trials met their primary endpoints and showed rapid symptom control in chronic spontaneous urticariaNext Novozymes delivers results within expectations in the first half of 2023 and narrows the full year outlook Related Stories Machine Learning News Software Development OCC Enhances Operational Efficiency with AWS GenAI Solutions Data Center News Vector Capital Originates $50 Million Loan for Sylvan’s Strategic Combination with Andy J. Egan Co., Inc. News Qlik Delivers Secure, Open Access to Trusted Data in Any Tool News Soldo’s 2025 Winter Launch Helps Finance Keep Spend in Flow News G42 Receives U.S. Approval for Advanced AI Chip Exports, Enabling Full-Scale Deployment of Trusted AI Infrastructure News Cloudera Reinforces Commitment to Saudi Vision 2030 with plans to launch its data and AI platform on the AWS Saudi Arabia Region